MAP.AX - Microba Life Sciences Limited

ASX - ASX Delayed price. Currency in AUD
+0.0050 (+1.85%)
At close: 02:54PM AEST
Stock chart is not supported by your current browser
Previous close0.2700
Bid0.2700 x N/A
Ask0.2750 x N/A
Day's range0.2700 - 0.2750
52-week range0.1350 - 0.4500
Avg. volume354,409
Market cap94.637M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.30
  • GlobeNewswire

    Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

    Combination of DNA biomarkers with microbiome biomarkers has potential to enhance technical profile of novel pancreatic cancer screening test Joint research project to discover disease specific microbiome biomarkers BERKELEY, Calif. and MAINZ, Germany, May 10, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a research collaboration with Microba Life S

  • Business Wire

    Microba Launches Next Generation Healthcare Testing

    BRISBANE, Australia, February 28, 2023--Microba Life Sciences Limited (ASX: MAP) ("Microba"), a precision microbiome company, is pleased to announce that it’s next generation testing product range, MetaXplore™ has been launched to healthcare professionals in Australia under a new brand, Co-Biome™. This delivers on the new healthcare product launch milestone prefaced in the FY22 Annual Report and updated in quarterly reports following the closed beta release in June 2022.

  • Business Wire

    Sonic Healthcare Acquires Strategic Stake in Microba Life Sciences, Establishes Significant Commercial Partnership

    BRISBANE, Australia, November 29, 2022--Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") is pleased to announce that leading medical diagnostics provider Sonic Healthcare Limited (ASX: SHL) ("Sonic") has agreed to invest $17.8m to acquire a 19.99% shareholding in Microba. In addition, Sonic is seeking to acquire options for an additional 5% equity position, subject to shareholder approval. Exercise of the options by Sonic would result in a further investment of $7.5m in Micr

  • Business Wire

    SYNLAB and Microba reinforce their combined expertise and expand strategic agreement on advanced gut microbiome test myBIOME

    BRISBANE, Australia, October 27, 2022--SYNLAB, the leader in medical diagnostic services and specialty testing in Europe, and Microba Life Sciences (Microba), a global leader in the analysis of complex gut microbiomes, have expanded their strategic agreement to broaden geographic and market availability of the microbiome test myBIOME across Europe and Latin America.

  • Simply Wall St.

    We're Keeping An Eye On Microba Life Sciences' (ASX:MAP) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...